drugset / Trial / NCT01313533

Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

NCT01313533 ↗

Phase 1/2 Unknown 540 enrolled St. Luke's Hospital, Chesterfield, Missouri
RandomizedFactorialQuadruple-blindPrevention

Summary

The purpose of this study is to study the effects of polyarginine treated vein grafts on graft patency for patients undergoing coronary artery bypass surgery.

Timeline

Start
2015-03
Primary completion
2019-12
Completion
2021-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Polyarginine Unknown — —

Indications